Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects

Abstract

1. To evaluate the effect of bifendate on the pharmacokinetics of talinolol, 16 unrelated male healthy subjects were selected for this study. After repeated oral administration of placebo or bifendate (three times daily for 14 days), the plasma concentration of talinolol was measured by high-performance liquid chromatography-electrospray mass spectrometry. This study was carried out in a randomized, single-blinded, placebo-controlled, crossover manner.

2. After the treatment of bifendate, the area under the curve (AUC_0–∞) was decreased significantly by 11.2% (90% confidence interval (CI), 7.3–12.4%; p = 0.001), and the C_max value of talinolol was decreased by approximately 9.7% (90% CI, 5.5–11.4%; p = 0.001). The oral clearance of talinolol was increased significantly by 13.1% (90% CI, 8.0–14.4%; p = 0.001).

3. The results suggest that the treatment of bifendate can decrease the plasma concentration of talinolol in healthy subjects.

Keywords::

• Bifendate
• talinolol
• pharmacokinetics

Acknowledgements

This work was supported by research grants from the National Natural Science Foundation of China (Grant Number 30672497), the China Medical Board of New York (Grant Number 01-755), and the Hunan Health Research Foundation of Traditional Chinese Medicine (Grant Number 204041).

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.